Physician profile
Hani Alsharif
NPI 1598974149
$1,734.80
in general payments reported to CMS, 2019-2025
19 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $234 · 2021: $17.15 · 2022: $149 · 2023: $95.85 · 2024: $354 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $48.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.51 |
| Education | $48.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $330.35 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $264.40 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $235.36 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $149.45 | 2019-2025 | Rayaldee |
| Amgen INC. | $142.77 | 2022-2025 | Krystexxa, Tavneos |
| Ani Pharmaceuticals, INC. | $111.25 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $96.12 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $81.32 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $45.83 | 2022-2023 | Tarpeyo |
| Horizon Therapeutics Plc | $38.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.93 | 2024 | |
| Alexion Pharmaceuticals, INC. | $34.46 | 2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $32.92 | 2019 | |
| Vifor Pharma, INC. | $30.74 | 2020 | |
| Ardelyx, INC. | $26.64 | 2024 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $25.53 | 2023 | |
| Fresenius USA Marketing, INC. | $23.30 | 2022 | |
| Baxter Healthcare | $21.84 | 2023 | Renal - Pd |
| Akebia Therapeutics INC | $9.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Alsharif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.